Revolutionizing Retinal Edema Treatment with Next-Generation Ocular Delivery Systems
Legal Citation
Summary of the Inventive Concept
A paradigm shift in treating retinal edema, leveraging cutting-edge technologies to create a new generation of targeted, personalized, and non-invasive ocular delivery systems.
Background and Problem Solved
The original patent addressed retinal edema treatment with cell-permeant therapeutics, but its limitations include non-targeted delivery, potential side effects, and lack of real-time monitoring. The new inventive concept overcomes these limitations by introducing nanocarrier-based delivery devices, personalized treatment approaches, real-time monitoring capabilities, and non-invasive delivery methods.
Detailed Description of the Inventive Concept
The new inventive concept comprises four key components: (1) nanocarrier-based delivery devices engineered to bypass the blood-retina barrier and selectively target retinal Müller cells, (2) personalized treatment approaches using customized cocktails of cell-penetrating peptides and XIAP-BIR3 conjugates tailored to individual patients' genetic profiles and retinal edema severity, (3) real-time monitoring devices that detect changes in retinal thickness and transmit data to wearable devices, and (4) non-invasive delivery methods utilizing focused ultrasound and microbubbles to create temporary openings in the blood-retina barrier. These components work in concert to provide targeted, efficient, and personalized treatment of retinal edema.
Novelty and Inventive Step
The new inventive concept introduces a paradigm shift in retinal edema treatment by combining cutting-edge technologies to create a targeted, personalized, and non-invasive ocular delivery system. The novelty lies in the integration of nanocarrier-based delivery, personalized treatment approaches, real-time monitoring, and non-invasive delivery methods, which collectively overcome the limitations of the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different types of nanocarriers, varying the composition of the cell-penetrating peptides and XIAP-BIR3 conjugates, or incorporating additional therapeutic agents into the delivery system. Variations may also include adapting the real-time monitoring device for use in other ocular diseases or integrating the non-invasive delivery method with other therapeutic approaches.
Potential Commercial Applications and Market
The new inventive concept has significant commercial potential in the ocular disease treatment market, with potential applications in treating diabetic macular edema, retinal vein occlusion, and other retinal diseases. The market for ocular disease treatments is projected to grow significantly in the coming years, driven by an aging population and increasing prevalence of ocular diseases.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/55 |
| A | A61 | A61K9/0048 |
| A | A61 | A61K47/64 |
| A | A61 | A61P27/02 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Ocular therapeutics and drug delivery systems, specifically focused on retinal disease treatment with an emphasis on targeted molecular delivery techniques, cell-penetrating peptides, and advanced drug formulation strategies
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or pharmaceutical scientist with expertise in ocular drug delivery, molecular conjugation techniques, nanotechnology, and experience with developing targeted therapeutic interventions for retinal diseases
Obviousness Rationale
A PHOSITA would recognize that the PTD's disclosed variations represent predictable extensions of the source patent's core technology by applying known drug delivery enhancement strategies to the existing XIAP-BIR3 conjugate approach. The proposed nanocarrier, personalized delivery, and monitoring technologies are logical progressions that leverage established principles of targeted molecular therapeutics and would be obvious to implement given the existing foundational patent.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,609 |
|---|---|
| Title | Ocular delivery of cell permeant therapeutics for the treatment of retinal edema |
| Assignee(s) | The Trustees of Columbia University in the City of New York |